39 related articles for article (PubMed ID: 31138901)
21. [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):323-6. PubMed ID: 27067847
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer.
Sui G; Qiu Y; Yu H; Kong Q; Zhen B
Oncol Lett; 2019 Jan; 17(1):944-950. PubMed ID: 30655852
[TBL] [Abstract][Full Text] [Related]
23. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles.
Imperial R; Ahmed Z; Toor OM; Erdoğan C; Khaliq A; Case P; Case J; Kennedy K; Cummings LS; Melton N; Raza S; Diri B; Mohammad R; El-Rayes B; Pluard T; Hussain A; Subramanian J; Masood A
Mol Cancer; 2018 Dec; 17(1):177. PubMed ID: 30577807
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?
Ibrahim S; Girault A; Ohresser M; Lereclus E; Paintaud G; Lecomte T; Raoul W
Clin Colorectal Cancer; 2018 Mar; 17(1):e109-e113. PubMed ID: 29153431
[TBL] [Abstract][Full Text] [Related]
25. Colorectal Cancer Incidence Trend and Projections in Tunisia (1994 - 2024).
Khiari H; Ben Ayoub HW; Ben Khadhra H; Hsairi M
Asian Pac J Cancer Prev; 2017 Oct; 18(10):2733-2739. PubMed ID: 29072401
[TBL] [Abstract][Full Text] [Related]
26. Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.
Wheat CL; Clark-Snustad K; Devine B; Grembowski D; Thornton TA; Ko CW
Gastroenterol Res Pract; 2016; 2016():1632439. PubMed ID: 27293427
[TBL] [Abstract][Full Text] [Related]
27. Cytokine-Induced Modulation of Colorectal Cancer.
Mager LF; Wasmer MH; Rau TT; Krebs P
Front Oncol; 2016; 6():96. PubMed ID: 27148488
[TBL] [Abstract][Full Text] [Related]
28. Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy.
Omrane I; Medimegh I; Baroudi O; Ayari H; Bedhiafi W; Stambouli N; Ferchichi M; Kourda N; Bignon YJ; Uhrhammer N; Mezlini A; Bougatef K; Benammar-Elgaaied A
PLoS One; 2015; 10(6):e0128911. PubMed ID: 26083022
[TBL] [Abstract][Full Text] [Related]
29. Association between Toll-like receptor 4 and interleukin 17 gene polymorphisms and colorectal cancer susceptibility in Northeast China.
Zhu L; Wang Y; Jie G; Chi Q; Zhou J; Cui B; Piao D; Zhao Y
Med Oncol; 2014 Oct; 31(10):73. PubMed ID: 25216863
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases.
Tseng JY; Yang CY; Liang SC; Liu RS; Yang SH; Lin JK; Chen YM; Wu YC; Jiang JK; Lin CH
Clin Cancer Res; 2014 Jun; 20(11):2885-97. PubMed ID: 24677375
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-17: a promoter in colorectal cancer progression.
Wu D; Wu P; Huang Q; Liu Y; Ye J; Huang J
Clin Dev Immunol; 2013; 2013():436307. PubMed ID: 24382972
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma.
Chung YC; Chaen YL; Hsu CP
Anticancer Res; 2006; 26(5B):3905-11. PubMed ID: 17094421
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Bedoui S; Dallel M; Barbirou M; Stayoussef M; Mokrani A; Mezlini A; Bouhaouala B; Almawi WY; Yacoubi-Loueslati B
Cancer Gene Ther; 2020 May; 27(5):311-318. PubMed ID: 31138901
[TBL] [Abstract][Full Text] [Related]
34. [Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):321-3. PubMed ID: 20723426
[No Abstract] [Full Text] [Related]
35. [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
Kumamoto K; Ishibashi K; Ishida H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():494-9. PubMed ID: 22214010
[No Abstract] [Full Text] [Related]
36. The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
Lee JJ; Chu E
Oncology (Williston Park); 2018 Sep; 32(9):437-42, 444. PubMed ID: 30248163
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
